Platform325 Hudson Street 4th Floor, New York, NY 10013, USAFounded 2013· One of 203 Platform companies tracked by AMPulse
Develops 3D bioprinters and bioprinted tissue constructs for medical research and cultivated meat, including the FABION bioprinter and in situ portable systems.
CEO / Founder
Yakov Balakhovsky
Team Size
11-50
Stage
Active
Total Funding
$5.2M
Latest Round
Seed
Key Investors
379 Number of Investors
Technology & Products
Key Products
FABION bioprinter; OrganAut bioprinter; In situ portable bioprinters; Bioprinted tissue and organ constructs; Tissue arrays
Technological Advantage
Proprietary bioprinting technologies for creating complex 3D tissue constructs; vertically integrated model from R&D to commercial manufacturing; early mover in space-based bioprinting applications.
Differentiation
Value Proposition
Enables rapid biofabrication of 3D tissue and organ constructs for drug discovery, disease modeling, and alternative protein production, reducing reliance on traditional 2D models and animal testing.
How They Differentiate
Offers a broader product range including both bioprinters and bioprinted tissues, with unique capabilities in microgravity bioprinting and cultivated meat applications, unlike competitors focused primarily on hardware or specific tissue models.
Market & Competition
Target Customers
Pharmaceutical companies, research institutions, cultivated meat producers
Industry Verticals
Biotechnology; Pharmaceutical; Medical Research; Cultivated Meat
Launched OrganAut bioprinter to International Space Station in 2018 for microgravity bioprinting experiments; Printed and implanted murine thyroid gland construct in laboratory animals; Ranked among top 20 companies in global 3D bioprinting market
VIVAX BIO operates a vertically integrated bioprinting platform that spans hardware, materials, and finished tissue constructs, targeting pharmaceutical companies, research institutions, and cultivated meat producers. Unlike competitors focused solely on bioprinter sales or specific tissue models, the company offers both the FABION and OrganAut bioprinters alongside bioprinted tissue arrays, enabling rapid biofabrication for drug discovery and disease modeling while reducing reliance on animal testing.
The company's core technologies include material extrusion (MEX), material jetting (MJT), and vat photopolymerization (VPP) adapted for cell-laden bioinks. Its product line ranges from benchtop systems like the FABION to in situ portable bioprinters designed for direct surgical repair. The OrganAut bioprinter was launched to the International Space Station in 2018 for microgravity bioprinting experiments, a capability that differentiates VIVAX BIO from peers such as Cellink, Organovo, and Aspect Biosystems.
Customer segments span biotechnology, pharmaceutical R&D, and cultivated meat production, where the company's tissue constructs serve as alternatives to traditional 2D cell cultures and animal models. The subsidiary 3D Bioprinting Solutions has demonstrated in vivo implantation of bioprinted murine thyroid gland constructs, indicating progress toward functional organ replacement. With $5.2 million in disclosed funding and a small team of 1-10 employees, VIVAX BIO occupies an emerging niche but faces scale-up challenges against better-capitalized competitors in the bioprinting space.
Competitive Intelligence
Competitors, SWOT analysis, and investment insights